<html><head><link rel="stylesheet" type="text/css" href="css.css"></head><h1 id="artitle">A Vaccine Breakthrough<br></h1><p id="artcont">But amid the gloom comes some light: A trial by the drug maker Pfizer has returned preliminary results suggesting that its vaccine is 90 percent effective in preventing Covid-19. Even more promising, the timeline — contingent on benchmarks being reached and approval being granted — is quite short. There could be enough of the vaccine for 20 million Americans by January. With the virus raging, how strong is this new ray of hope? INSIDE THE DAILY For an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter. Read the latest edition here. Carl Zimmer, a science writer and author of the “Matter” column for The New York Times. Pfizer has announced positive early results from its coronavirus vaccine trial, cementing the lead in a frenzied global race that has unfolded at record-breaking speed. Meet the couple behind the German company, BioNTech, that partnered with Pfizer to develop the vaccine. There are a lot of ways to listen to The Daily. Here’s how. 